CM338 not checked

Keymed Biosciences Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
IgA Nephropathy
Main trialPhase 2
“This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.”In the company’s words, NCT05775042 on ClinicalTrials.gov

Other drugs for IgA Nephropathy

All 39 drugs for IgA Nephropathy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2027 Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Phase 1Completed 27 Jul 2022 Single Ascending Dose Study of CM338 in Healthy Volunteers
Phase 1Completed 4 Nov 2022 Multiple Ascending Dose Study of CM338 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CM338

Following is part of Solo: you see every change to CM338 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in